We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly Adds to its Diabetes Portfolio With Purchase of Protomer for $1 Billion
Eli Lilly Adds to its Diabetes Portfolio With Purchase of Protomer for $1 Billion
Rounding out its holdings in the diabetes space, Eli Lilly has bought the remaining shares of biotech Protomer Technologies, which has a peptide- and protein-engineering platform that can identify and synthesize molecules that sense glucose.